Table 1.
Patient characteristics
| Characteristics | Evaluable patients (n = 38) |
|---|---|
| Age (y), median (range) | 58 (19-72) |
| Sex, no. (%) | |
| Female | 17 (44.7) |
| Male | 21 (55.3) |
| Race, no. (%) | |
| Asian | 1 (2.6) |
| Black or African American | 1 (2.6) |
| Unknown | 4 (10.5) |
| White | 32 (84.2) |
| Diagnosis, no. (%) | |
| ALL | 4 (10.5) |
| AML | 17 (44.7) |
| CLL | 1 (2.6) |
| CML | 2 (5.3) |
| MDS | 13 (34.2) |
| NHL T cell | 1 (2.6) |
| Chemotherapy regimen, no. (%) | |
| MAC BU 5300-FLU | 18 (47.4) |
| RIC BU 3500-FLU | 1 (2.6) |
| RIC MEL FLU | 19 (50.0) |
| Donor, no. (%) | |
| Related | 13 (34.2) |
| Unrelated | 25 (65.8) |
| Stem cell source, no. (%) | |
| PBSCs | 38 (100) |
ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; BU, busulfan; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; FLU, fludarabine; MAC, myeloablative; MDS, myelodysplastic syndrome; Mel, melphalan; NHL, non-Hodgkin lymphoma; RIC, reduced intensity.